

NCT02664558 Raw comparison:

Summary:
CHIA has 43 criteria while your personal folder has 45 criteria
Total found criteria: 43/43
Total not Found: 0/43
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male or female 18-75 years old                     │ Male or female 18-75 years old                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has a diagnosis of WHO Group 1 PAH                 │ Has a diagnosis of WHO Group 1 PAH                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Right heart catheterization performed at Screening │ Right heart catheterization performed at Screening │
│ with results that are                              │ with results that are                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Mean pulmonary arterial pressure ≥25 mmHg (at      │ Mean pulmonary arterial pressure ≥25 mmHg (at      │
│ rest) and                                          │ rest) and                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pulmonary venous hypertension (measured as         │ Pulmonary venous hypertension (measured as         │
│ pulmonary capillary wedge pressure (PCWP) ≤15 mmHg │ pulmonary capillary wedge pressure (PCWP) ≤15 mmHg │
│ If PCWP is not available then mean left atrial     │ If PCWP is not available then mean left atrial     │
│ pressure or left ventricular end-diastolic         │ pressure or left ventricular end-diastolic         │
│ pressure ≤15 mmHg in the absence of left atrial    │ pressure ≤15 mmHg in the absence of left atrial    │
│ obstruction and                                    │ obstruction and                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pulmonary vascular resistance (PVR) ≥300 dyn•s/cm5 │ Pulmonary vascular resistance (PVR) ≥300 dyn•s/cm5 │
│ (3 75 Wood units)                                  │ (3 75 Wood units)                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has WHO/NYHA-FC of II or III                       │ Has WHO/NYHA-FC of II or III                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Be on stable dose of at least one of the following │ Be on stable dose of at least one of the following │
│ PAH-specific therapies endothelin receptor         │ PAH-specific therapies endothelin receptor         │
│ antagonist an agent acting on the nitric oxide     │ antagonist an agent acting on the nitric oxide     │
│ pathway (phosphodiesterase type 5 inhibitor or     │ pathway (phosphodiesterase type 5 inhibitor or     │
│ soluble guanylate cyclase stimulator) and/or a     │ soluble guanylate cyclase stimulator) and/or a     │
│ prostacyclin or prostacyclin analog                │ prostacyclin or prostacyclin analog                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has a 6-minute walk distance that is ≥150 and ≤500 │ Has a 6-minute walk distance that is ≥150 and ≤500 │
│ meters                                             │ meters                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have a ventilation-perfusion scan that rules out   │ Have a ventilation-perfusion scan that rules out   │
│ thromboembolic disease                             │ thromboembolic disease                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Exclusions Related to Cardiovascular Disease       │ Exclusions Related to Cardiovascular Disease       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of uncontrolled hypertension               │ History of uncontrolled hypertension               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Persistent hypotension at Screening                │ Persistent hypotension at Screening                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence or history of left-sided heart disease    │ Evidence or history of left-sided heart disease    │
│ and/or clinically significant cardiac disease in   │ and/or clinically significant cardiac disease in   │
│ which pulmonary hypertension is more likely WHO    │ which pulmonary hypertension is more likely WHO    │
│ Group 2                                            │ Group 2                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute decompensated heart failure within 1 month   │ Acute decompensated heart failure within 1 month   │
│ of Screening                                       │ of Screening                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Recent initiation (<8 weeks from Screening) or     │ Recent initiation (\<8 weeks from Screening) or    │
│ planned initiation of cardiopulmonary              │ planned initiation of cardiopulmonary              │
│ rehabilitation exercise program                    │ rehabilitation exercise program                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Exclusions Related to Pulmonary Disease            │ Exclusions Related to Pulmonary Disease            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Newly diagnosed with PAH and not on PAH-specific   │ Newly diagnosed with PAH and not on PAH-specific   │
│ therapy                                            │ therapy                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pulmonary hypertension due to                      │ Pulmonary hypertension due to                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncorrected congenital systemic-to-pulmonary shunt │ Uncorrected congenital systemic-to-pulmonary shunt │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pulmonary veno-occlusive disease and/or pulmonary  │ Pulmonary veno-occlusive disease and/or pulmonary  │
│ capillary hemangiomatosis                          │ capillary hemangiomatosis                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Persistent pulmonary hypertension of the newborn   │ Persistent pulmonary hypertension of the newborn   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ WHO clinical classification Groups 2-5             │ WHO clinical classification Groups 2-5             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of significant airway and/or parenchymal  │ Evidence of significant airway and/or parenchymal  │
│ lung disease                                       │ lung disease                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic infection related to tuberculosis or       │ Chronic infection related to tuberculosis or       │
│ fungal or mycobacterial disease                    │ fungal or mycobacterial disease                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Exclusions Based on Other Medical Conditions       │ Exclusions Based on Other Medical Conditions       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic infections including but not limited to    │ Chronic infections including but not limited to    │
│ tuberculosis (TB) hepatitis B virus (HBV) or       │ tuberculosis (TB) hepatitis B virus (HBV) or       │
│ hepatitis C virus (HCV)                            │ hepatitis C virus (HCV)                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of portal hypertension or chronic liver    │ History of portal hypertension or chronic liver    │
│ disease including positive serology for infection  │ disease including positive serology for infection  │
│ with HCV and/or HBV                                │ with HCV and/or HBV                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of active infection requiring intravenous │ Evidence of active infection requiring intravenous │
│ or oral antibiotics within 4 weeks of Screening    │ or oral antibiotics within 4 weeks of Screening    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Body mass index ≥35 0 at Screening                 │ Body mass index ≥35 0 at Screening                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of obstructive sleep apnea                 │ History of obstructive sleep apnea                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of malignancy within the last 5 years      │ History of malignancy within the last 5 years      │
│ except nonmelanoma skin cancer and cervical        │ except nonmelanoma skin cancer and cervical        │
│ carcinoma in situ treated with curative intent     │ carcinoma in situ treated with curative intent     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Neuropsychiatric disorders/symptoms or             │ Neuropsychiatric disorders/symptoms or             │
│ psychological conditions                           │ psychological conditions                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy or breast-feeding                        │ Pregnancy or breast-feeding                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior treatment with B cell or lymphocyte-         │ Prior treatment with B cell or lymphocyte-         │
│ depleting agents (eg rituximab Campath)            │ depleting agents (eg rituximab Campath)            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Exclusions Based on Concomitant Medication Use     │ Exclusions Based on Concomitant Medication Use     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent regular use of another leukotriene      │ Concurrent regular use of another leukotriene      │
│ pathway inhibitor including over-the-counter       │ pathway inhibitor including over-the-counter       │
│ medications or herbal remedies                     │ medications or herbal remedies                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Exclusions Based on Laboratory Values              │ Exclusions Based on Laboratory Values              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant/chronic renal insufficiency            │ Significant/chronic renal insufficiency            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Transaminases (alanine transaminase aspartate      │ Transaminases (alanine transaminase aspartate      │
│ transaminase) levels >3 × upper limit of normal    │ transaminase) levels \>3 × upper limit of normal   │
│ (ULN) and/or bilirubin level >2 × ULN              │ (ULN) and/or bilirubin level \>2 × ULN             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Absolute neutrophil count <1500 mm3                │ Absolute neutrophil count \<1500 mm3               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin concentration <9 g/dL at Screening      │ Hemoglobin concentration \<9 g/dL at Screening     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hepatic dysfunction as defined by Child-Pugh Class │ Hepatic dysfunction as defined by Child-Pugh Class │
│ B or C                                             │ B or C                                             │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 75 Years │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛